MarcErnstoffMD

PubMed

• 653 citations
  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
  Bryan J. Schneider, Jarushka Naidoo, Bianca Santomasso, Christina Lacchetti, Sherry Adkins
  Journal of Clinical Oncology. 2021-11-01
• 173 citations
  Systemic Therapy for Melanoma: ASCO Guideline.
  Rahul Seth, Hans Messersmith, Varinder Kaur, John M. Kirkwood, Ragini R. Kudchadkar
  Journal of Clinical Oncology. 2020-03-31
• 829 citations
  Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
  Kim Margolin, Marc S. Ernstoff, Omid Hamid, Donald P. Lawrence, David F. McDermott
  The Lancet. Oncology. 2012-05-01

Journal Articles

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain  
  Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
• Hierarchical clustering analysis of immune measures to monitor patients with gliomas receiving immunotherapy  
  Fadul CE, Fisher JL, Hampton TH, Ernstoff MS, Journal for ImmunoTherapy of Cancer, 1/1/2014
• Multiple murine BRAF (V600E) melanoma cell lines with sensitivity to PLX4032  
  Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE, Pigment Cell Melanoma Res, 1/1/2014
• Personalized Medicine: Some Things to Consider  
  Pipas JM, Lewis LD, Ernstoff MS, Tsongalis GJ, Oncology & Hematology Review, 1/1/2013
• Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma  
  Poklepovic A, Youseffian L, Winning M, Birdsell CA, Crosby NA, Ramakrishnan V, Ernstoff MS, Roberts JD, Invest New Drugs, 1/1/2013
• mTOR Pathway and mTOR Inhibitors in Cancer Therapy  
  Ernstoff MS, Br J Clin Pharmacol, 1/25/2011
• Letter to the Editor  
  Ernstoff MS, Fisher J, Seigne JD, Szczepiorkowski ZM, Crosby NA, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Schwaab T, Schwarzer A, Wolf B, Noelle RJ, Clin Cancer Res, 1/1/2009
• Factors associated with atypical moles in New Hampshire, USA  
  Titus-Ernstoff L, Ding J, Perry AE, Spencer SK, Cole BF, Ernstoff MS, Acta Derm Venereol, 1/1/2007
• Program to Support Safe Administration of Oral Chemotherapy  
  Birner, AM, Bedell, MK, Avery JT and Ernstoff MS, J Oncol Practice, 1/1/2006
• Response to Letters to the Editor of a) L Kretschmer and C Neumann, Dept of Dermatology, University of Gottinggen, Gottinggen, Germany and b) B Coldiron and S Dinehart...  
  Kirkwood JM, Ibrahim J, Manola J, Sondak VK, Ernstoff MS and Agarwala SS, J Clin Oncol, 1/1/2002
• The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choridoidal Melanoma I: Characteristics of patients enrolled and ...  
  Collaborative Ocular Melanoma Study Group, Am J Opthalmol, 1/1/1998
• The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choridoidal Melanoma III: Local Complication and Observations Fol...  
  Collaborative Ocular Melanoma Study (COMS) Group, Am J Opthalmol, 1/1/1998
• The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choridoidal Melanoma II: Initial mortality findings COMS report n...  
  Collaborative Ocular Melanoma Study Group, Am J Opthalmol, 1/1/1998
• HER-2/neu Targeted Immunotherapy: A Pilot Study of Multi-Dose MDX-210 in Patients with Breast or Ovarian Cancers that Overexpress HER-2/neu and a Report of an increase...  
  Kaufman PA, Guyre PM, Lewis LD, Valone FH, Memoli V, Wells W, Deo YM, Ernstoff MS, Fisher J, Mrozek-Orlowski M, Phipps K and Fanger MW, Tumor Targeting, 1/1/1996
• Letter to the Editor: The pathogenesis of disseminated intravascular coagulation in sepsis  
  Logan TF, Virji MA, Gooding WE, Bontempo FA, Ernstoff MS and Kirkwood JM, JAMA, 1/1/1994
• Synergistic actions of biological agents and chemotherapy  
  Ernstoff MS, Biotherapy & Cancer, 1/1/1990
• Biological response modifiers in the therapy of metastatic melanoma  
  Kirkwood JM, Logan TF, Vlock DR and Ernstoff MS, Pigment Cell, 1/1/1990
• umor necrosis factor alpha: A potential anti-cancer agent for superficial bladder cancer  
  Ernstoff MS, Bahnson RR and Hakala T, Surgical Rounds, 1/1/1990
• The usefulness of frequent skin examination for the early detection of second primary cutaneous melanoma  
  Titus-Ernstoff L, Ernstoff MS, Kirkwood JM, Barnhill RL, Fine J and Duray PH, Cancer Detect Prevent, 1/1/1989
• Editorial: Fluorouracil, interferon-alpha and colon cancer: rational pursuit of synergism between antimetabolites and biologicals  
  Ernstoff MS, Lembersky BC and Kirkwood JM, J Clin Oncol, 1/1/1989
• A clinical update: The role of interferon in the biotherapy of solid tumors  
  Kirkwood JM and Ernstoff MS, Onc Nurse Forum, 1/1/1988
• Dysplastic nevi in association with multiple primary melanoma  
  Titus-Ernstoff L, Duray PH, Ernstoff MS, Barnhill RL, Horn PL and Kirkwood JM, Cancer Res, 1/1/1988
• Technique for catheterization and cystoscopic evaluation of cynomolgus monkey bladder  
  Bahnson RR, Ballou BT, Ernstoff MS, Schwentker FN and Hakala TR, Lab Animal Sciences, 1/1/1988
• Immunotherapeutic approaches in the treatment and management of gastrointestinal malignancies  
  Ernstoff MS and Kirkwood JM, Surg Res, 1/1/1988
• Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma  
  Duray PH and Ernstoff MS, Arch Dermatol, 1/1/1987
• Join now to see all

Books/Book Chapters

• The Molecular Basis of Cancer 
  Chapter: Molecular Basis for Treating Cutaneous Melanoma. 
  Page 591 - 600Ernstoff MSEditors: Mendelsohn, Gray, Howley, Israel, Thompson.Elsevier, Philadelphia, PA2014
• Neurological Complications of Systemic Cancer and Antineoplastic Therapy 
  Chapter: Neurologic complications associated to genitourinary cancer. 
  Page 336 - 349Kasbari, SS, Ernstoff, MS, Fadul, CEEditors: Newton/Malkin.Informa Healthcare, New York2010
• 2003 American Society of Clinical Oncology Educational Booklet 
  Chapter: Update: Medical Therapy for Cutaneous Melanoma. 
  Page 198 - 207Ernstoff, MS, Tretter CPG and Titus-Ernstoff LEditors: MC Perry.2003
• Atlas of the Prostate 
  Chapter: Clinical Aspects of Prostate Cancer. 
  Ernstoff, MSEditors: C Reginald and MD Bruskewitz.Current Medicine, Inc., Philadelphia2002
• Principles and Practice of the Biologic Therapy of Cancer 
  Chapter: Interferon-alpha and-Beta: Clinical Applications Renal Cell Cancer. 
  Tretter C, Savage Paul D, Muss Hyman B and Ernstoff MSEditors: SA Rosenberg.Lippincott Williams & Wilkins, BaltimoreEdition 3rd,2001
• Strategies in Adjuvant Therapy 
  Chapter: Prostate Carcinoma. 
  Page 105 - 131Curtis MR, Heaney JA, Amdur RJ, Schned AR, Harris R and Ernstoff MSEditors: JM Kirkwood.2000
• Strategies in Adjuvant Therapy 
  Chapter: Prostatic Carcinoma. 
  Page 2 - 26Ernstoff, MSEditors: JM Kirkwood.Martin Dunitz Ltd., London1999
• Drug Information for the Health Care Professional, USP DI 
  Ernstoff MS (Contributor: Division of Information Development)Micromedex, Inc., EnglewoodEdition 19th,1999
• Uretal Carcinoma 
  Ernstoff MS and Heaney JAEditors: L Gomella and M Damba M.Williams & Wilkins, Baltimore1999
• The Cecil Textbook of Medicine 
  Chapter: Nonmetastatic Effects of Cancer: Other Systems. 
  Ernstoff MS and Meehan KEdition 21st,1999
• Urology Annual 1997 (Volume 11) 
  Chapter: Using PSA Response to Predict Outcome Following Radiotherapy for Prostate Cancer 
  Page 25 - 37Amdur RJ, Leopold KA, Ernstoff MS, Schned AR and Heaney JAEditors: S Rous.W.W. Norton & Co., Inc., New York1997
• The Chemotherapy Sourcebook 
  Chapter: Toxicity of Biologic Response Modifiers. 
  Page 833 - 841Borden EC, Crawford J, Cross A, Dillman RO, Ernstoff MS, Hawkins MJ and Heyman MWilliams and Wilkins, Baltimore1996
• Urologic Cancer 
  Chapter: Biologic therapy of renal cell carcinoma. 
  Gorsch SM and Ernstoff MSEditors: MS Ernstoff, JA Heaney and RE Peschel.Blackwell Science, Boston1996
• Current Cancer Therapeutics 
  Chapter: Genitourinary cancer. 
  Page 198 - 214Ernstoff MS, Bahnson RR and Heaney JAEditors: JM Kirkwood.PhiladelphiaEdition 2nd,1996
• Comprehensive Textbook of Genitourinary Oncology 
  Chapter: Management of metastatic renal cell carcinoma: Chemotherapy, hormonal therapy and interferons. 
  Gorsch SM and Ernstoff MSEditors: NJ Vogelzang and BJ Miles.Williams & Wilkins, Baltimore1995
• Cecil Textbook of Medicine 
  Chapter: Paraneoplastic syndromes. 
  Meehan KR and Ernstoff MSEdition 19th,1995
• Tumor Immunology and Cancer Therapy 
  Chapter: Combination Cytokine Therapy in Cancer. 
  Page 273 - 279Ernstoff MSEditors: RH Goldfarb and TL Whiteside.Marcel Dekker, Inc., New York1994
• Current Cancer Therapeutics 
  Chapter: Genitourinary Cancers Protocols. 
  Ernstoff MS, Bahnson RR and Heaney JANCI1994
• 1994 Urology Annual Vol. 8 
  Chapter: Immunotherapy of Renal Cell Carcinoma. 
  Page 145 - 158Ernstoff MSEditors: SN Rous.Norton Medical Books, W. W. Norton Co., New York1994
• Current Therapy in Genitourinary Surgery 
  Chapter: Deeply invasive transitional cell carcinoma. 
  Page 78 - 80Ernstoff MS and Hakala TB.C. Decker, Inc. Mosby-Year Book1992
• Biologic Therapy of Cancer 
  Chapter: Interferons in the therapy of cutaneous melanoma. 
  Page 311 - 333Kirkwood JM and Ernstoff MSEditors: VT DeVita Jr, S Hellman and SA Rosenberg.JB Lippincott Co., Philadelphia1991
• Biological Agents in the Treatment of Melanoma and Other Cancers: Proceedings of the International Conference, Newcastle, NSW, 1990 
  Chapter: New approaches to the use of IL-2 in melanoma: adoptive cellular therapy utilizing purified populations of A-LAK effectors. 
  Page 40 - 46Kirkwood JM, Ernstoff MS, Vlock DR, Herberman RB and Whiteside TLEditors: P Hersey.1990
• Biological Agents in the Treatment of Melanoma and Other Cancers: Proceedings of the International Conference, Newcastle, NSW, 1990 
  Chapter: A synthesis of biological approaches to melanoma under study at the Pittsburgh Cancer Institute. 
  Page 527 - 533Kirkwood JM, Ernstoff MS, Vlock DR, Opacic D, Boucher Y and Jain REditors: P Hersey.1990
• Biological Agents in the Treatment of Melanoma and Other Cancers: Proceedings of the International Conference, Newcastle, NSW, 1990 
  Chapter: The role of interferons in the therapy of melanoma. 
  Page 303 - 322Kirkwood JM and Ernstoff MSEditors: P Hersey.1990
• The Biological and Clinical Applications of Interleukin-2 
  Chapter: Approaches to immunotherapy with defined populations of IL-2 cultured NK cells, immune T cells or tumour infiltrating lymphocytes. 
  Page 111 - 119Heberman RB, Basse P, Jain RK, Medler RJ, Goldfarb RH, Gorelik E, Ernstoff MS, Kirkwood JM and Whiteside TLEditors: RC Rees.IRL Press, Oxford1990
• Join now to see all

Abstracts/Posters

• A Phase 1 Study of Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in Combination with Sunitinib, Pazopanib or Ipilimumab in Patients (pts) with Metastatic Renal Cell Carc...
  Infante J, Heng D, Rini B, Plimack E, McDermott D, Kollmannsberger C, Reaume N, Spratlin J, Knox J, Voss M, Pal S, Hammers H, Ernstoff MS, ASCO 2013, Chicago, IL, 1/3/2013
• Melanoma masquerading as atypical squamous proliferation.
  Tiger JB, Torti DC, Pace NC, Chapman MS, Coffing BN, Wells G, Lacy SR, Yan S, Storm CA, Ernstoff MS, Barth, Jr. RJ, Gross & Microscopic Dermatology Symposium, 70th AAD Annual Meeting, San Diego, CA, 1/16/2012
• Merkel Cell Polyomavirus Detection In Extrapulmonary Small Cell Carcinoma.
  Lefferts JA, Hourdequin KC, Hitzelberger WA, Tafel L, Pipas JM, Ernstoff MS, Tsongalis GJ, USCAP Annual Meeting, San Antonio, TX, 1/26/2011
• Survival and safety of ipilimumab-treated patients with melanoma and brain metastases.
  Margolin K, Hodi FS, McDermott DF, Lawrence D, Hamid O, Puzanov I, Thompson JA, Ernstoff MS, Michener T, Heller KN, ESMO 2011, Providence, RI, 1/16/2011
• Clinical outcome of single agent volasertib (BI 6727) as second line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).
  Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Rosen P, Lin C-C, Mahoney J, Modi S, Lee P, Ernstoff MS, Su WC, Spira A, Ould Kaci M, Taube T, Watrous J, V..., ASCO, Chicago, IL, 1/3/2011
• Phase II Study of Single Agent Volasertib (BI 6727), a Polo-Like Kinase 1 Inhibitor, for Second-Line Treatment of Urothelial Cancer.
  Ernstoff MS, ASCO GU Cancer Symposium, 1/1/2011
• Rapid identification of somatic mutations in melanoma cell lines.
  Schwab MC, Jung S, Fisher JL, Ernstoff MS, Tsongalis GJ, J Molec Diagn; Association for Molecular Pathology, Grapevine, TX, Nov. 17-19, 2011, 1/1/2011
• Phase 2 trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure.
  Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Qian J, Ricker JL, M. Michaelson D, ASCO Annual Meeting, Chicago, IL, 1/4/2010
• Clinical Electron Paramagnetic Resonance (EPR) Oximetry Using India Ink.
  Williams BB, Khan N, Zaki B, Hartford A, Ernstoff MS, Swartz HM, Adv Exp Med Biol, 1/1/2010
• phase II study of bevacizumab (b) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal carcinoma (mRCC): A Cytokine Working Group Study (CWGS).
  Dandamudi UB, Ghebremichael S, Sosman JA, Regan MM, Atkins MB, Clark J, Dutcher JP, Curti BD, Vaishampayan UN, Ernstoff MS, Proc ASCO, 1/1/2010
• Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with comp...
  Lawson DH, Lee SJ, Tarhini AA, Margolin KA, Ernstoff MS, Kirkwood JM, Proc ASCO, 1/1/2010
• Treatment of colorectal cancer patients after resection of metastases with a tumor lysate pulsed dendritic cell vaccine: association between immune response and recurr...
  Barth RJ Jr, Fischer DA, Channon JY, Ernstoff MS, Wallace PK, Proc AACR, 1/1/2010
• Clinical correlation of variable expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: Analysis of a tissue microarray using immunostaini...
  Lipe B, Petrella B, Gui J, Wason S, Schned A, Ernstoff MS, Proc AACR, 1/1/2010
• Phase 2 study of recombinant IL-21 (rIL-21) plus sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Final results.
  Bhatia S, Heath E, Puzanov I, Miller W, Curti B, Gordon M, Ernstoff MS, Hausman D, Hunder N, Thompson J, 2009 ASCO Annual Meeting, Orlando, FL, 1/29/2009
• Phase II Trial of ABT-869 in Advanced Renal Cell Carcinoma (RCC) After Sunitinib Failure: Efficacy and Safety Results.
  Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Qian J, Ricker JL, M. Michaelson D, 2009 ASCO Annual Meeting, Orlando, FL, 1/29/2009
• Phase II Trial of ABT-869 in Advanced Renal Cell Carcinoma (RCC) After Sunitinib Failure: Efficacy and Safety Results.
  Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Qian J, Ricker JL, M. Michaelson D, 2009 ECCO/ESMO Meeting, Berlin, Germany, 1/23/2009
• A phase 1 clinical trial of immune response and safety of an active immunotherapy regimen co-targeting PRAME and PSMA antigens in subjects with advanced solid malignan...
  Obrocea M, Vogelzang N, Cranmer L, Ernstoff MS, Weber J, Marshall J, Rosario D, Qiu Z, Bot A, AACR 100th Annual Meeting, Denver, CO, 1/18/2009
• Immune Mobilization with IL-2 and Growth Factors: Differential in Vivo Effects of the NKG2D Receptor on CD8+ and CD56+ Effector Cells.
  Meehan KR, Hill, JH, Ernstoff MS, Sentman C, Blood; 50th ASH Annual Meeting and Exposition, 1/6/2008
• Immune Mobilization with Direct In-Vivo Effector Response: Clinical Trial with Favorable Implications for Post-Transplant Outcome. Session Type: Publication Only.
  Hill JM, Wu J, Webber SM, Root LD, Kimtis EA, Williams IC, Ernstoff MS, Szczepiorkowski ZM, Sentman CL, Meehan KR, ASH 49th Annual Meeting and Exposition, 1/1/2007
• Phase I trial of dacarbazine and bortezomib in melanoma and soft tissue sarcoma.
  Roberts JD, Ernstoff MS, Birdsell C, Proc ASCO, 1/1/2006
• Chemo-hormonal therapy for biochemical progression of prostrate cancer.
  Taplin M, Xie W, Morganstern D, Bubley G, Ernstoff M, Regan M, Proc ASCO, 1/1/2006
• Primary Adrenocortical Tumors: EGFR, c-Kit and Her-2/neu receptor staining patterns.
  Samnotra V, Memoli VA, Ernstoff MS, Tretter CP, Heaney JA, Korc M, Farell TJ, Simmons P, Proc ASCO, 1/1/2005
• Phase 2 trial of talabostat in Stage IV melanoma.
  Redman BG, Ernstoff MS, Gajewski TF, Cunningham C, Lawson DH, Gregoire L, Haltom E, Uprichard MJ, Proc ASCO, 1/1/2005
• A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from mela...
  Atkins MB, Sosman J, Agarwala S, Logan T, Clark J, Ernstoff M, Lawson D, Dutcher J, Weiss G, Urba W, Margolin K, Proc ASCO, 1/1/2005
• A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209-2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts).
  Ernstoff M, Carrillo C, Urba W, Flaherty L, Clark J, Dutcher J, Margolin K, Atkins M, Sosman JA, Proc ASCO, 1/1/2005
• Join now to see all

Lectures

• A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Management of Immune-Checkpoint Toxicity 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• "Research Method" 
  1/1/2014
• "Renal Cancer" 
  1/1/2014
• "Melanoma Therapy" 
  1/1/2014
• "Renal Cell Carcinoma" 
  Lebanon, NH - 1/9/2013
• Fellows Lecture: "Research in academic settings and private practice settings" 
  Dartmouth-Hitchcock Medical Center, Lebanon, NH - 1/8/2013
• "Advances in Melanoma, Basal Cell Cancer, and Targeted Therapy" 
  Caracas, Venezuela - 1/1/2013
• "Dartmouth/AIM" 
  Lebanon, NH - 1/22/2012
• "Kidney: Novel Immunotherapeutic Strategies in 2012: CTLA4, PD1 & Lessons From Melanoma" 
  Burlington, VT - 1/1/2012
• "Insights from immune monitoring of patients with metastatic RCC and GBM Implications for treatment Development" 
  San Diego, CA - 1/1/2012
• "Renal Cell Cancer therapy" 
  Montreal, Canada - 1/29/2011
• "New therapies for Melanoma" 
  Mt. Washington, NH - 1/28/2011
• "Update on Melanoma Care" 
  Johannesburg, South Africa - 1/3/2011
• "Yin and Yang: Immunotherapy for RCC" 
  Buffalo, NY - 1/1/2010
• "Update on Cytokine Working Group Studies" 
  Chicago, IL - 1/1/2010
• "Kidney Cancer" 
  Beth Israel Deaconess Medical Center, Boston, MA - 1/1/2009
• "Vaccine for Renal Cancer" 
  Herlev, Denmark - 1/1/2009
• "New approaches to Melanoma" 
  1/1/2009
• Medical Grand Rounds: "Predictions- From Masses to One: Exploring the use of Gene Expression to Predict Response in Metastatic Renal Carcinoma (RCC) Patients" 
  Dartmouth-Hitchcock Medical Center, Lebanon, NH - 1/1/2009
• "New Treatment in Melanoma" 
  Lebanon, NH - 1/1/2008
• "Stage by Stage: Who needs PET-CT in melanoma?" 
  Bretton Woods, NH - 1/1/2008
• "TORISEL (temsirolimus) injection: An mTOR Inhibitor for the Treatment of Advanced RCC" 
  Wichita, KS - 1/1/2008
• "Vaccines and Dendritic Cell Therapy" 
  Chicago, IL - 1/1/2008
• "DC vaccines" 
  Anaheim, CA - 1/1/2007
• Join now to see all

Other

• "Television Interview on Vaccine Therapy for Cancer" 
  Marc Stuart Ernstoff, MD, "Globo Sciencia", Globo TV
  Brazil - 1/1/2005
• Consistency of Measurements and Observations from Echograms made Centrally in the Collaborative Ocular Melanoma Study. 
  Collaborative Ocular Melanoma Study (COMS) Group, COMS Report No. 13
  1/1/2000
• In Vivo-Beschreibung tumorinfiltrierender Dendritischer Zellen (TiDCs) im humanen Nierenzellkarzinom (NCC)- Phaenotyp und Funktion. 
  Schwaab T, Atzpodien J, Heaney JA, Ernstoff MS, Deutsche Gesellschaft fur Urologie
  1/1/1998
• "Prostate Cancer. Boston: Blackwell Science" 
  Ernstoff MS, Heaney JA, and Peschel RE (Editors)
  1/1/1998
• "Testicular and Penile Cancer. Boston: Blackwell Science" 
  Ernstoff MS, Heaney JA, and Peschel RE (Editors)
  1/1/1998
• "Urologic Cancer. Boston: Blackwell Science" 
  Ernstoff MS, Heaney JA and Peschel RE (Editors)
  1/1/1997
• The Collaborative Ocular Melanoma Study (COMS0 Randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma: I. Characteristics of Patients Screened for E... 
  Collaborative Ocular Melanoma Study Group, COMS Report No. 5
  1/1/1996
• In vitro generation and in vivo effects of adherent lymphokine activated killer A-LAK cells and IL2 in patients with solid tumors. 
  Whiteside TL, Ernstoff MS, Nair S, Kirkwood JM and Herberman RB, 6th Intl Natural Killer Cell Workshop; Goslar, 1989, pp. 293-202 (Karger, pub.)
  Basel - 1/1/1990
• Toxicity and antitumor effects of recombinant alpha-2 interferon in a phase I trial by the intramuscular route. 
  Kirkwood JM, Ernstoff MS, Fusi S, Davis CA, Ariyan S and Rudnick SA, Proc XIII Int. Cong. of Chemotherapy
  1/1/1983
• Treatment of cerebral metastases. 
  Ernstoff MS and Cadman EC, Connecticut Medicine
  1/1/1982
• Join now to see all